ROBUST:来那度胺联合R-CHOP对比安慰剂联合R-CHOP治疗初治ABC型弥漫大B细胞淋巴瘤的III期研究
ROBUST是一项全球III期随机对照研究,在570例初治ABC型DLBCL患者中比较来那度胺联合R-CHOP(R2-CHOP)与安慰剂联合R-CHOP的疗效。R2-CHOP的安全性特征与各单药治疗一致,未发现新的安全性信号。
要点
- 在全部ABC型DLBCL患者中,R2-CHOP较安慰剂联合R-CHOP未显著改善PFS。
- 在高危疾病患者中观察到PFS趋势 favoring R2-CHOP。
- R2-CHOP组3/4级中性粒细胞减少(60% vs 48%)和贫血(22% vs 14%)发生率较高。
核心结论
- R2-CHOP的安全性特征与各单药治疗一致,未发现新的安全性信号。
研究设计与样本
- 全球、III期、随机、双盲、安慰剂对照研究。
- 共纳入570例初治ABC型DLBCL患者,按1:1随机分配至R2-CHOP组(n=285)或安慰剂/R-CHOP组(n=285)。
- 组织学和细胞起源类型在随机分组前由中心病理学前瞻性分析确认。
- 患者接受来那度胺口服15 mg/d,第1-14天/21天周期,联合标准R-CHOP21方案,共6个周期。
- 主要终点为独立中心放射学评估的无进展生存期(PFS)。
主要发现
- 多数患者完成6个周期治疗:R2-CHOP组74%,安慰剂/R-CHOP组84%。
- R2-CHOP组与安慰剂/R-CHOP组最常见的3/4级不良事件包括中性粒细胞减少(60% vs 48%)、贫血(22% vs 14%)、血小板减少(17% vs 11%)和白细胞减少(14% vs 15%)。
- 在高危疾病患者中观察到PFS趋势 favoring R2-CHOP。
关键数值与推荐
- R2-CHOP方案:来那度胺口服15 mg/d,第1-14天/21天周期,联合标准R-CHOP21,共6个周期。
- 3/4级中性粒细胞减少发生率:R2-CHOP组60%,安慰剂/R-CHOP组48%。
- 3/4级贫血发生率:R2-CHOP组22%,安慰剂/R-CHOP组14%。
临床怎么用
- 对于初治ABC型DLBCL患者,R2-CHOP较标准R-CHOP未显著改善PFS,不支持在全部ABC型患者中常规加用来那度胺。
- 在高危ABC型DLBCL患者中可考虑R2-CHOP,但需权衡增加的血液学毒性。
- R2-CHOP方案的安全性特征与各单药治疗一致,未发现新的安全性信号。
局限性
- 主要终点PFS未达到,未报告总生存期(OS)数据。
- 高危亚组的PFS趋势为探索性分析,未提供该亚组的风险比和置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal of the global, phase III ROBUST study was to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL. METHODS: Histology and cell-of-origin type were prospectively analyzed by central pathology prior to random assignment and study treatment. Patients with ABC-DLBCL received lenalidomide oral 15 mg/d, days 1-14/21 plus standard R-CHOP21 versus placebo/R-CHOP21 for six cycles. The primary end point was progression-free survival (PFS) per independent central radiology review. RESULTS: A total of 570 patients with ABC-DLBCL (n = 285 per arm) were stratified by International Prognostic Index score, age, and bulky disease, and randomly assigned to R2-CHOP or placebo/R-CHOP. Baseline demographics were similar between arms. Most patients completed six cycles of treatment: 74% R2-CHOP and 84% placebo/R-CHOP. The most common grade 3/4 adverse events for R2-CHOP versus placebo/R-CHOP were neutropenia (60% v 48%), anemia (22% v 14%), thrombocytopenia (17% v 11%), and leukopenia (14% v 15%). The primary end point of PFS was not met, with a hazard ratio of 0.85 (95% CI, 0.63 to 1.14) and P = .29; median PFS has not been reached for either arm. PFS trends favoring R2-CHOP over placebo/R-CHOP were seen in patients with higher-risk disease. CONCLUSION: ROBUST is the first DLBCL phase III study to integrate biomarker-driven identification of eligible ABC patients. Although the ROBUST trial did not meet the primary end point of PFS in all patients, the safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
引用
- Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021. PMID: 33621109. doi:10.1200/JCO.20.01366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。